Published in Viruses on February 21, 2012
CCR5 is a receptor for Staphylococcus aureus leukotoxin ED. Nature (2012) 1.85
Small molecule inhibitors of CXCR4. Theranostics (2013) 1.30
Flaviviruses: braking the entering. Curr Opin Virol (2013) 1.02
Combinatorial anti-HIV gene therapy: using a multipronged approach to reach beyond HAART. Gene Ther (2013) 0.93
A model of peptide triazole entry inhibitor binding to HIV-1 gp120 and the mechanism of bridging sheet disruption. Biochemistry (2013) 0.90
Inhibition of the Hantavirus Fusion Process by Predicted Domain III and Stem Peptides from Glycoprotein Gc. PLoS Negl Trop Dis (2016) 0.79
A Novel Two-Tag System for Monitoring Transport and Cleavage through the Classical Secretory Pathway - Adaptation to HIV Envelope Processing. PLoS One (2013) 0.79
Characterization of antiviral activity of benzamide derivative AH0109 against HIV-1 infection. Antimicrob Agents Chemother (2013) 0.78
Antibody epitopes on g protein-coupled receptors mapped with genetically encoded photoactivatable cross-linkers. Biochemistry (2014) 0.77
Blocking interaction of viral gp120 and CD4-expressing T cells by single-stranded DNA aptamers. Int J Biochem Cell Biol (2014) 0.77
Genome-Edited T Cell Therapies. Curr Stem Cell Rep (2017) 0.76
Flunarizine arrests hepatitis C virus membrane fusion. Hepatology (2015) 0.75
Template-constrained cyclic sulfopeptide HIV-1 entry inhibitors. Org Biomol Chem (2013) 0.75
Covalent conjugation of a peptide triazole to HIV-1 gp120 enables intramolecular binding site occupancy. Biochemistry (2014) 0.75
Recent Insights into the HIV/AIDS Pandemic. Microb Cell (2016) 0.75
Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med (1998) 53.26
HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science (1996) 26.19
Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature (1998) 24.69
Identification of a major co-receptor for primary isolates of HIV-1. Nature (1996) 23.81
The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell (1986) 22.26
HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature (1996) 20.59
CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science (1996) 18.53
Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell (1996) 17.81
An improved zinc-finger nuclease architecture for highly specific genome editing. Nat Biotechnol (2007) 17.80
The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell (1996) 17.13
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A (2008) 16.54
Atomic structure of the ectodomain from HIV-1 gp41. Nature (1997) 16.31
Core structure of gp41 from the HIV envelope glycoprotein. Cell (1997) 16.18
Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature (1996) 15.91
Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol (2008) 14.75
A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell (1996) 14.64
Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science (1993) 13.87
Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science (1998) 12.81
Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med (2009) 11.68
CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature (1996) 11.37
Change in coreceptor use correlates with disease progression in HIV-1--infected individuals. J Exp Med (1997) 11.01
Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS. Cell (1986) 10.70
The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med (1996) 10.62
The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature (1996) 9.25
Induction of CD4-dependent cell fusion by the HTLV-III/LAV envelope glycoprotein. Nature (1986) 8.36
The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc Natl Acad Sci U S A (1997) 8.27
Molecular architecture of native HIV-1 gp120 trimers. Nature (2008) 8.04
Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol (1992) 7.92
Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med (1993) 7.21
Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med (2005) 7.01
Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol (2010) 6.55
Biosynthesis, cleavage, and degradation of the human immunodeficiency virus 1 envelope glycoprotein gp160. Proc Natl Acad Sci U S A (1988) 6.33
HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med (2011) 6.30
Atomic structure of a thermostable subdomain of HIV-1 gp41. Proc Natl Acad Sci U S A (1997) 5.76
Capture of an early fusion-active conformation of HIV-1 gp41. Nat Struct Biol (1998) 5.62
A role for carbohydrates in immune evasion in AIDS. Nat Med (1998) 5.06
HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells. Nat Immunol (2008) 5.01
HIV-1 inhibition by a peptide. Nature (1993) 5.01
Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation. Blood (2010) 4.99
Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution. J Virol (1992) 4.86
Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission. J Clin Invest (1994) 4.63
HIV enters cells via endocytosis and dynamin-dependent fusion with endosomes. Cell (2009) 4.63
Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J Virol (1998) 4.48
Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4. Science (2007) 4.35
Inhibition of furin-mediated cleavage activation of HIV-1 glycoprotein gp160. Nature (1992) 4.16
Human immunodeficiency virus infection of CD4-bearing cells occurs by a pH-independent mechanism. EMBO J (1988) 3.98
Identification of the fusion peptide of primate immunodeficiency viruses. Science (1989) 3.83
A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res Hum Retroviruses (1993) 3.80
Folding, interaction with GRP78-BiP, assembly, and transport of the human immunodeficiency virus type 1 envelope protein. J Virol (1991) 3.62
RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med (2010) 3.53
Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding. J Exp Med (1997) 3.48
Zinc finger nucleases: custom-designed molecular scissors for genome engineering of plant and mammalian cells. Nucleic Acids Res (2005) 3.47
Viral phenotype and immune response in primary human immunodeficiency virus type 1 infection. J Infect Dis (1992) 3.16
Selective transmission of CCR5-utilizing HIV-1: the 'gatekeeper' problem resolved? Nat Rev Microbiol (2006) 3.13
Critical role for beta7 integrins in formation of the gut-associated lymphoid tissue. Nature (1996) 3.11
A mutation in the human immunodeficiency virus type 1 transmembrane glycoprotein gp41 dominantly interferes with fusion and infectivity. Proc Natl Acad Sci U S A (1992) 3.01
The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor. J Virol (2002) 2.90
Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. J Infect Dis (2006) 2.74
Two distinct CCR5 domains can mediate coreceptor usage by human immunodeficiency virus type 1. J Virol (1997) 2.67
The integrin alpha4beta7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1. Proc Natl Acad Sci U S A (2009) 2.30
HIV-1 envelope proteins complete their folding into six-helix bundles immediately after fusion pore formation. Mol Biol Cell (2003) 2.18
Involvement of clathrin-mediated endocytosis in human immunodeficiency virus type 1 entry. J Virol (2005) 2.12
Selective depletion of rectal lamina propria rather than lymphoid aggregate CD4 lymphocytes in HIV infection. Clin Exp Immunol (1997) 1.82
Entry inhibitors in the treatment of HIV-1 infection. Antiviral Res (2009) 1.72
Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist. Transfusion (2005) 1.71
Use of coreceptors other than CCR5 by non-syncytium-inducing adult and pediatric isolates of human immunodeficiency virus type 1 is rare in vitro. J Virol (1998) 1.69
Role of N-linked glycans in a human immunodeficiency virus envelope glycoprotein: effects on protein function and the neutralizing antibody response. J Virol (2002) 1.69
Safety and efficacy of a lentiviral vector containing three anti-HIV genes--CCR5 ribozyme, tat-rev siRNA, and TAR decoy--in SCID-hu mouse-derived T cells. Mol Ther (2007) 1.63
RNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice. Mol Ther (2009) 1.55
V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies. PLoS Pathog (2007) 1.55
Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140. J Virol (2001) 1.55
Engineering HIV-resistant human CD4+ T cells with CXCR4-specific zinc-finger nucleases. PLoS Pathog (2011) 1.50
A novel CCR5 mutation common in sooty mangabeys reveals SIVsmm infection of CCR5-null natural hosts and efficient alternative coreceptor use in vivo. PLoS Pathog (2010) 1.48
A pièce de resistance: how HIV-1 escapes small molecule CCR5 inhibitors. Curr Opin HIV AIDS (2009) 1.41
Design, engineering, and characterization of zinc finger nucleases. Biochem Biophys Res Commun (2005) 1.39
T-cell protection and enrichment through lentiviral CCR5 intrabody gene delivery. Gene Ther (2006) 1.38
DC-SIGN and DC-SIGNR: helping hands for HIV. Trends Immunol (2001) 1.34
A pharmacokinetic-pharmacodynamic model for the mobilization of CD34+ hematopoietic progenitor cells by AMD3100. Clin Pharmacol Ther (2005) 1.24
Allogeneic haematopoietic stem cell transplantation in patients with human immunodeficiency virus: the experiences of more than 25 years. Clin Exp Immunol (2011) 1.23
Chemokine and orphan receptors in HIV-2 and SIV tropism and pathogenesis. Virology (1999) 1.17
Conversion of the FokI endonuclease to a universal restriction enzyme: cleavage of phage M13mp7 DNA at predetermined sites. Gene (1985) 1.15
Primary infection by a human immunodeficiency virus with atypical coreceptor tropism. J Virol (2011) 1.12
Characterization of envelope glycoprotein gp41 genotype and phenotypic susceptibility to enfuvirtide at baseline and on treatment in the phase III clinical trials TORO-1 and TORO-2. AIDS Res Hum Retroviruses (2006) 1.10
Novel interfering bifunctional molecules against the CCR5 coreceptor are efficient inhibitors of HIV-1 infection. Mol Ther (2003) 1.09
Preintegration HIV-1 inhibition by a combination lentiviral vector containing a chimeric TRIM5 alpha protein, a CCR5 shRNA, and a TAR decoy. Mol Ther (2009) 1.03
Inhibition of HIV-1 infection by a unique short hairpin RNA to chemokine receptor 5 delivered into macrophages through hematopoietic progenitor cell transduction. J Gene Med (2010) 1.02
Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine. AIDS (2003) 1.02
The T4 glycoprotein is a cell-surface receptor for the AIDS virus. Cold Spring Harb Symp Quant Biol (1986) 0.95
Functional role of the glycan cluster of the human immunodeficiency virus type 1 transmembrane glycoprotein (gp41) ectodomain. J Virol (1993) 0.86
The epidemiology of HIV coreceptor tropism. Eur J Med Res (2007) 0.86
Immunopathology of human immunodeficiency virus infection in the gastrointestinal tract. Springer Semin Immunopathol (1997) 0.83
HIV vaccine design and the neutralizing antibody problem. Nat Immunol (2004) 9.48
Public health. A sound rationale needed for phase III HIV-1 vaccine trials. Science (2004) 5.31
Diversity of receptors binding HIV on dendritic cell subsets. Nat Immunol (2002) 4.63
Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics. Proc Natl Acad Sci U S A (2002) 4.48
Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J Virol (2007) 4.45
DC-SIGN and DC-SIGNR bind ebola glycoproteins and enhance infection of macrophages and endothelial cells. Virology (2003) 3.20
Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR. J Virol (2003) 3.10
Constitutive and induced expression of DC-SIGN on dendritic cell and macrophage subpopulations in situ and in vitro. J Leukoc Biol (2002) 2.93
West Nile virus discriminates between DC-SIGN and DC-SIGNR for cellular attachment and infection. J Virol (2006) 2.79
Phenotypic properties of transmitted founder HIV-1. Proc Natl Acad Sci U S A (2013) 2.75
A rapid and quantitative assay for measuring antibody-mediated neutralization of West Nile virus infection. Virology (2005) 2.60
Expression of DC-SIGN by dendritic cells of intestinal and genital mucosae in humans and rhesus macaques. J Virol (2002) 2.46
The entry of entry inhibitors: a fusion of science and medicine. Proc Natl Acad Sci U S A (2003) 2.43
Differential N-linked glycosylation of human immunodeficiency virus and Ebola virus envelope glycoproteins modulates interactions with DC-SIGN and DC-SIGNR. J Virol (2003) 2.42
Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection. J Exp Med (2003) 2.37
Truncation of the cytoplasmic domain induces exposure of conserved regions in the ectodomain of human immunodeficiency virus type 1 envelope protein. J Virol (2002) 2.23
N-linked glycosylation of west nile virus envelope proteins influences particle assembly and infectivity. J Virol (2005) 2.00
Castanospermine, a potent inhibitor of dengue virus infection in vitro and in vivo. J Virol (2005) 1.97
A replication-competent, neutralization-sensitive variant of simian immunodeficiency virus lacking 100 amino acids of envelope. J Virol (2002) 1.97
Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin α4β7. PLoS Pathog (2012) 1.88
Characterization of neutralizing antibodies to West Nile virus. Virology (2005) 1.81
Simultaneous zinc-finger nuclease editing of the HIV coreceptors ccr5 and cxcr4 protects CD4+ T cells from HIV-1 infection. Blood (2013) 1.80
Quantitative expression and virus transmission analysis of DC-SIGN on monocyte-derived dendritic cells. J Virol (2002) 1.78
Retroviral mRNA nuclear export elements regulate protein function and virion assembly. EMBO J (2004) 1.77
Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization. J Virol (2005) 1.73
Entry inhibitors in the treatment of HIV-1 infection. Antiviral Res (2009) 1.72
HR-2 mutations in human immunodeficiency virus type 1 gp41 restore fusion kinetics delayed by HR-1 mutations that cause clinical resistance to enfuvirtide. J Virol (2009) 1.69
Impact of mutations in the coreceptor binding site on human immunodeficiency virus type 1 fusion, infection, and entry inhibitor sensitivity. J Virol (2004) 1.69
CD4 independence of simian immunodeficiency virus Envs is associated with macrophage tropism, neutralization sensitivity, and attenuated pathogenicity. J Virol (2002) 1.66
Molecular mechanisms of HIV entry. Adv Exp Med Biol (2012) 1.55
V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies. PLoS Pathog (2007) 1.55
Phenotypic and immunologic comparison of clade B transmitted/founder and chronic HIV-1 envelope glycoproteins. J Virol (2011) 1.55
An infectious West Nile virus that expresses a GFP reporter gene. Virology (2005) 1.51
Human immunodeficiency virus type 2. J Gen Virol (2002) 1.50
Comparing antigenicity and immunogenicity of engineered gp120. J Virol (2005) 1.50
Engineering HIV-resistant human CD4+ T cells with CXCR4-specific zinc-finger nucleases. PLoS Pathog (2011) 1.50
A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5. J Virol (2010) 1.47
The core domain of chemokines binds CCR5 extracellular domains while their amino terminus interacts with the transmembrane helix bundle. J Biol Chem (2002) 1.46
HIV: cell binding and entry. Cold Spring Harb Perspect Med (2012) 1.46
Modulation of Env content in virions of simian immunodeficiency virus: correlation with cell surface expression and virion infectivity. J Virol (2004) 1.44
BACE overexpression alters the subcellular processing of APP and inhibits Abeta deposition in vivo. J Cell Biol (2005) 1.34
Beta-secretase processing in the trans-Golgi network preferentially generates truncated amyloid species that accumulate in Alzheimer's disease brain. J Biol Chem (2002) 1.31
Enhanced exposure of the CD4-binding site to neutralizing antibodies by structural design of a membrane-anchored human immunodeficiency virus type 1 gp120 domain. J Virol (2009) 1.26
The neutralizing antibody response against West Nile virus in naturally infected horses. Virology (2006) 1.26
The location of asparagine-linked glycans on West Nile virions controls their interactions with CD209 (dendritic cell-specific ICAM-3 grabbing nonintegrin). J Biol Chem (2006) 1.25
HIV type 1 from a patient with baseline resistance to CCR5 antagonists uses drug-bound receptor for entry. AIDS Res Hum Retroviruses (2010) 1.25
Glu11 site cleavage and N-terminally truncated A beta production upon BACE overexpression. Biochemistry (2002) 1.25
Secretion and intracellular generation of truncated Abeta in beta-site amyloid-beta precursor protein-cleaving enzyme expressing human neurons. J Biol Chem (2002) 1.24
HIV-1 resistance to CCR5 antagonists associated with highly efficient use of CCR5 and altered tropism on primary CD4+ T cells. J Virol (2010) 1.23
Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors. J Virol (2007) 1.20
A yeast glycoprotein shows high-affinity binding to the broadly neutralizing human immunodeficiency virus antibody 2G12 and inhibits gp120 interactions with 2G12 and DC-SIGN. J Virol (2009) 1.19
Cellular localization and antigenic characterization of crimean-congo hemorrhagic fever virus glycoproteins. J Virol (2005) 1.19
Focused dampening of antibody response to the immunodominant variable loops by engineered soluble gp140. AIDS Res Hum Retroviruses (2008) 1.19
The chemokine stromal cell-derived factor-1 promotes the survival of embryonic retinal ganglion cells. J Neurosci (2003) 1.15
Prospects of HIV-1 entry inhibitors as novel therapeutics. Rev Med Virol (2004) 1.14
Transmitted/founder and chronic HIV-1 envelope proteins are distinguished by differential utilization of CCR5. J Virol (2012) 1.13
Primary infection by a human immunodeficiency virus with atypical coreceptor tropism. J Virol (2011) 1.12
Identification of a novel C-terminal cleavage of Crimean-Congo hemorrhagic fever virus PreGN that leads to generation of an NSM protein. J Virol (2007) 1.10
Rift valley fever virus infection of human cells and insect hosts is promoted by protein kinase C epsilon. PLoS One (2010) 1.09
Inefficient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR5 complex at low cell surface CCR5 densities. Virology (2009) 1.07
AIDS models: microbicides could learn from vaccines. Nat Med (2002) 1.06
Development and characterization of a Rift Valley fever virus cell-cell fusion assay using alphavirus replicon vectors. Virology (2006) 1.04
Unique pattern of convergent envelope evolution in simian immunodeficiency virus-infected rapid progressor macaques: association with CD4-independent usage of CCR5. J Virol (2003) 1.03
Antibodies against Manalpha1,2-Manalpha1,2-Man oligosaccharide structures recognize envelope glycoproteins from HIV-1 and SIV strains. Glycobiology (2009) 1.03
HIV-1 entry inhibitors: new targets, novel therapies. Immunol Lett (2003) 1.01
Yeast-elicited cross-reactive antibodies to HIV Env glycans efficiently neutralize virions expressing exclusively high-mannose N-linked glycans. J Virol (2010) 1.01
The transmembrane domain region of nicastrin mediates direct interactions with APH-1 and the gamma-secretase complex. J Biol Chem (2003) 1.00
Functional impact of HIV coreceptor-binding site mutations. Virology (2006) 1.00
Determinants within gp120 and gp41 contribute to CD4 independence of SIV Envs. Virology (2004) 0.99
Kinetic studies of HIV-1 and HIV-2 envelope glycoprotein-mediated fusion. Retrovirology (2006) 0.98
Qualitative T-helper responses to multiple viral antigens correlate with vaccine-induced immunity to simian/human immunodeficiency virus infection. J Virol (2004) 0.98
Presenilins are not required for A beta 42 production in the early secretory pathway. Nat Neurosci (2002) 0.98
Replication-competent variants of human immunodeficiency virus type 2 lacking the V3 loop exhibit resistance to chemokine receptor antagonists. J Virol (2007) 0.97
Membrane topology of gamma-secretase component PEN-2. J Biol Chem (2003) 0.96
The role of DC-SIGN and DC-SIGNR in HIV and Ebola virus infection: can potential therapeutics block virus transmission and dissemination? Expert Opin Ther Targets (2002) 0.96
Presence of broadly reactive and group-specific neutralizing epitopes on newly described isolates of Crimean-Congo hemorrhagic fever virus. J Gen Virol (2005) 0.96
Adaptive mutations in a human immunodeficiency virus type 1 envelope protein with a truncated V3 loop restore function by improving interactions with CD4. J Virol (2009) 0.96
Identification of gp120 binding sites on CXCR4 by using CD4-independent human immunodeficiency virus type 2 Env proteins. J Virol (2003) 0.95
Membrane topology and nicastrin-enhanced endoproteolysis of APH-1, a component of the gamma-secretase complex. J Biol Chem (2003) 0.95
Baseline resistance of primary human immunodeficiency virus type 1 strains to the CXCR4 inhibitor AMD3100. J Virol (2008) 0.95
Quantitative phosphoproteomics reveals extensive cellular reprogramming during HIV-1 entry. Cell Host Microbe (2013) 0.93
Endoproteolysis of beta-secretase (beta-site amyloid precursor protein-cleaving enzyme) within its catalytic domain. A potential mechanism for regulation. J Biol Chem (2003) 0.93
Presenilin modulates Pen-2 levels posttranslationally by protecting it from proteasomal degradation. Biochemistry (2004) 0.92
Amino acid 324 in the simian immunodeficiency virus SIVmac V3 loop can confer CD4 independence and modulate the interaction with CCR5 and alternative coreceptors. J Virol (2004) 0.91
N-terminal substitutions in HIV-1 gp41 reduce the expression of non-trimeric envelope glycoproteins on the virus. Virology (2007) 0.89
Quantitative phosphoproteomics of CXCL12 (SDF-1) signaling. PLoS One (2011) 0.88
Structure and function of CC-chemokine receptor 5 homologues derived from representative primate species and subspecies of the taxonomic suborders Prosimii and Anthropoidea. J Virol (2003) 0.88
Mutations in the C3 region of human and simian immunodeficiency virus envelope have differential effects on viral infectivity, replication, and CD4-dependency. Virology (2003) 0.88
Hemofiltrate CC chemokine 1[9-74] causes effective internalization of CCR5 and is a potent inhibitor of R5-tropic human immunodeficiency virus type 1 strains in primary T cells and macrophages. Antimicrob Agents Chemother (2002) 0.85
HIV transmission: closing all the doors. J Exp Med (2004) 0.85
Modulation of HIV and SIV neutralization sensitivity by DC-SIGN and mannose-binding lectin. Virology (2007) 0.85
Opportunities and challenges in targeting HIV entry. Curr Opin Pharmacol (2002) 0.83
Efficient production of Hantaan and Puumala pseudovirions for viral tropism and neutralization studies. Virology (2011) 0.83
N-glycosylation of human nicastrin is required for interaction with the lectins from the secretory pathway calnexin and ERGIC-53. Biochim Biophys Acta (2006) 0.82
Evolution of coreceptor use and CD4-independence in envelope clones derived from SIVsm-infected macaques. Virology (2003) 0.82
Kruppel-like factor 2 modulates CCR5 expression and susceptibility to HIV-1 infection. J Immunol (2012) 0.81
Identification and characterization of a potent, selective nonpeptide agonist of the CC chemokine receptor CCR8. Mol Pharmacol (2005) 0.81
A Potent, Broad-Spectrum Antiviral Agent that Targets Viral Membranes. Viruses (2010) 0.79
Distinct presenilin-dependent and presenilin-independent gamma-secretases are responsible for total cellular Abeta production. J Neurosci Res (2003) 0.78